中文

IDEXX Laboratories (IDXX)

Healthcare

Close on Nov 12, 2026 (from our latest Long View update): $698.02

Market value
$55.0Bat the Nov 12 close
Revenue growth
+12%12 months to Sep 30, 2026 (10-Q)
FCF margin
28%12 months to Sep 30, 2026 (10-Q)
Net debt
$651Mat Sep 30, 2026
Worst fall since listing
−81.4%Feb 5, 1996 to Apr 18, 1997; back to that high in Mar 2004

About the company

Latest

  • Up 21.8% Move
    IDEXX jumps 22% on a beat and raise despite fewer vet visits

The Long View

IDEXX grew revenue every year from 2021 to 2025, from $3.22B to $4.30B, and spent about as much on buybacks as it generated in free cash flow (operating cash flow minus capital spending; our calculation), while its share price swung widely.

Self-funding

▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash

Updated Nov 12, 2026

Read the Long View →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for IDEXX Laboratories, FY2009–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $1.0B in FY2009 to $4.3B in FY2025. Free cash flow was positive in 17 of the 17 years shown; FY2025: $1.1B. Each year's figures are in the table below. $0$1B$2B$3B$4B$5B ’09 ’11 ’13 ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $1.0B in FY2009 to $4.3B in FY2025.

Free cash flow was positive in 17 of the 17 years shown; FY2025: $1.1B.

Margins

Operating margin was 32% in FY2025, vs 26% in FY2020. Gross margin was 62% in FY2025, vs 58% in FY2020. Each year's figures are in the table below. 0%20%40%60%80% ’09’11’13’15’17’19’21’23’25

Operating margin was 32% in FY2025, vs 26% in FY2020.

Gross margin was 62% in FY2025, vs 58% in FY2020.

Diluted share count

The diluted share count fell 7% from FY2020 to FY2025, to 81M. Each year's figures are in the table below. 80M90M100M110M120M130M ’09’11’13’15’17’19’21’23’25

The diluted share count fell 7% from FY2020 to FY2025, to 81M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$4.3B62%32%$1.1B$1.2B$125M$1.1B
FY2024$3.9B61%29%$888M$929M$121M$808M
FY2023$3.7B60%30%$845M$907M$134M$773M
FY2022$3.4B60%27%$679M$543M$149M$394M
FY2021$3.2B59%29%$745M$756M$120M$636M
FY2020$2.7B58%26%$582M$648M$107M$541M
FY2019$2.4B57%23%$428M$459M$155M$304M
FY2018$2.2B56%22%$377M$400M$116M$284M
FY2017$2.0B56%21%$263M$373M$74M$299M
FY2016$1.8B55%20%$222M$339M$65M$274M
FY2015$1.6B56%19%$192M$222M$83M$139M
FY2014$1.5B55%18%$182M$236M$61M$175M
FY2013$1.4B55%19%$188M$246M$78M$168M
FY2012$1.3B54%20%$178M$222M$58M$165M
FY2011$1.2B53%19%$162M$218M$50M$168M
FY2010$1.1B52%18%$141M$179M$39M$140M
FY2009$1.0B51%17%$122M$175M$51M$124M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202581M$180M$848M$60M—$1.2B
FY202483M$288M$868M$60M—$837M
FY202384M$454M$948M$60M—$72M
FY202285M$113M$1.3B$50M—$820M
FY202187M$144M$851M$38M—$747M
FY202087M$384M$909M$31M—$183M
FY201988M$90M$988M$39M—$302M
FY201888M$124M$1.0B$25M—$369M
FY201790M$472M$1.3B$24M—$283M
FY201691M$392M$1.2B$20M—$304M
FY201594M$343M$1.2B$20M—$402M
FY2014102M$323M$899M$18M—$618M
FY2013108M$279M$428M$17M—$368M
FY2012112M$224M$215M$16M—$132M
FY2011116M$184M$246M$15M—$256M
FY2010119M$157M$132M$13M—$143M
FY2009121M$107M$123M$12M—$83M

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 12, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

  • Diluted shares are restated to the current share basis (stock splits or reverse splits), chaining year-over-year changes reported in each 10-K.

Returns by year

YearIDXXS&P 500
2019+40.4%+31.5%
2020+91.4%+18.4%
2021+31.7%+28.7%
2022−38.0%−18.1%
2023+36.1%+26.3%
2024−25.5%+25.0%
2025+63.6%+17.9%
2026 to date+1.9%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Healthcare

Questions about IDEXX Laboratories

How does IDEXX make money?
Mostly from tests that vets buy again and again: supplies for the IDEXX analyzers in their clinics, quick in-clinic test kits and its outside reference labs. These recurring diagnostics were about 79% of its $4.30 billion of revenue in 2025; analyzers, practice software, water tests and livestock tests make up the rest. More in the Long View →
What drives IDEXX's growth?
More testing per visit rather than more visits: IDEXX places analyzers such as inVue Dx in clinics, adds new tests to them, wins customers and raises prices. By its own measure, organic revenue grew 10% a year from 2020 to 2025. More in the Long View →
What could slow IDEXX's growth?
Fewer vet visits: most of its revenue comes from tests run on patients, and U.S. same-store clinical visits have been falling, by about 2% in 2025. IDEXX also names competition from Mars and Zoetis and pricing pressure from corporate hospital groups and buying consortiums as risks. More in the Long View →
How dependent is IDEXX on a few customers?
Not on customers: no customer accounted for more than 10% of revenue in 2025. It does depend on one supplier, Ortho-Clinical Diagnostics, for the slides used in its Catalyst chemistry analyzers, under agreements set to run until December 2044. More in the Long View →
Does IDEXX buy back its own shares?
IDEXX spent about $3.7 billion buying back 7.6 million shares from 2021 to 2025, about four times the new shares it issued, so shares outstanding fell 6.7%. It pays no dividend. More in the Long View →